Pfizer annual revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Pfizer Revenue Growth & History (PFE)
Pfizer reported $62.58B in revenue for fiscal 2025, a decrease of 1.65% from the previous fiscal year.
View full Pfizer company overviewPfizer annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $62.58B | −$1.05B | −1.65% |
| 2024 | 2024-12-31 | $63.63B | $12.71B | +24.97% |
| 2023 | 2023-12-31 | $50.91B | −$40.88B | −44.53% |
| 2022 | 2022-12-31 | $91.79B | $18.16B | +24.66% |
| 2021 | 2021-12-31 | $73.64B | $31.98B | +76.79% |
| 2020 | 2020-12-31 | $41.65B | $746.0M | +1.82% |
| 2019 | 2019-12-31 | $40.91B | $80.0M | +0.20% |
| 2018 | 2018-12-31 | $40.83B | −$11.72B | −22.31% |
| 2017 | 2017-12-31 | $52.55B | −$278.0M | −0.53% |
| 2016 | 2016-12-31 | $52.82B | $3.97B | +8.13% |
| 2015 | 2015-12-31 | $48.85B | −$754.0M | −1.52% |
| 2014 | 2014-12-31 | $49.60B | −$1.98B | −3.84% |
| 2013 | 2013-12-31 | $51.58B | −$3.07B | −5.62% |
| 2012 | 2012-12-31 | $54.66B | −$6.38B | −10.45% |
| 2011 | 2011-12-31 | $61.03B | −$4.13B | −6.34% |
| 2010 | 2010-12-31 | $65.17B | $15.90B | +32.26% |
| 2009 | 2009-12-31 | $49.27B | $973.0M | +2.01% |
| 2008 | 2008-12-31 | $48.30B | −$122.0M | −0.25% |
| 2007 | 2007-12-31 | $48.42B | — | — |
Pfizer quarterly revenue
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $15.03B | $381.0M | +2.60% |
| Q1 2026 | 2026-03-29 | $14.45B | $736.0M | +5.37% |
| Q4 2025 | 2025-12-31 | $17.56B | −$206.0M | −1.16% |
| Q3 2025 | 2025-09-28 | $16.65B | −$1.05B | −5.92% |
| Q2 2025 | 2025-06-29 | $14.65B | $1.37B | +10.31% |
| Q1 2025 | 2025-03-30 | $13.71B | −$1.16B | −7.82% |
| Q4 2024 | 2024-12-31 | $17.76B | $11.83B | +199.54% |
| Q3 2024 | 2024-09-29 | $17.70B | $4.21B | +31.21% |
| Q2 2024 | 2024-06-30 | $13.28B | $276.0M | +2.12% |
| Q1 2024 | 2024-03-31 | $14.88B | −$3.61B | −19.51% |
| Q4 2023 | 2023-12-31 | $5.93B | −$9.82B | −62.35% |
| Q3 2023 | 2023-10-01 | $13.49B | −$9.15B | −40.41% |
| Q2 2023 | 2023-07-02 | $13.01B | −$14.73B | −53.11% |
| Q1 2023 | 2023-04-02 | $18.49B | −$7.17B | −27.96% |
| Q4 2022 | 2022-12-31 | $15.75B | −$434.0M | −2.68% |
| Q3 2022 | 2022-10-02 | $22.64B | −$1.40B | −5.81% |
| Q2 2022 | 2022-07-03 | $27.74B | $8.84B | +46.79% |
| Q1 2022 | 2022-04-03 | $25.66B | $11.14B | +76.78% |
| Q4 2021 | 2021-12-31 | $16.19B | $4.76B | +41.65% |
| Q3 2021 | 2021-10-03 | $24.04B | $13.76B | +133.87% |
| Q2 2021 | 2021-07-04 | $18.90B | $9.04B | +91.60% |
| Q1 2021 | 2021-04-04 | $14.52B | $4.43B | +43.97% |
| Q4 2020 | 2020-12-31 | $11.43B | $9.58B | +520.02% |
| Q3 2020 | 2020-09-27 | $10.28B | −$2.40B | −18.95% |
| Q2 2020 | 2020-06-28 | $9.86B | −$3.40B | −25.63% |
| Q1 2020 | 2020-03-29 | $10.08B | −$3.04B | −23.14% |
| Q4 2019 | 2019-12-31 | $1.84B | $688.0M | +59.57% |
| Q3 2019 | 2019-09-29 | $12.68B | −$618.0M | −4.65% |
| Q2 2019 | 2019-06-30 | $13.26B | −$202.0M | −1.50% |
| Q1 2019 | 2019-03-31 | $13.12B | $212.0M | +1.64% |
| Q4 2018 | 2018-12-31 | $1.16B | −$12.55B | −91.57% |
| Q3 2018 | 2018-09-30 | $13.30B | $130.0M | +0.99% |
| Q2 2018 | 2018-07-01 | $13.47B | $570.0M | +4.42% |
| Q1 2018 | 2018-04-01 | $12.91B | $127.0M | +0.99% |
| Q4 2017 | 2017-12-31 | $13.70B | $76.0M | +0.56% |
| Q3 2017 | 2017-10-01 | $13.17B | $123.0M | +0.94% |
| Q2 2017 | 2017-07-02 | $12.90B | −$251.0M | −1.91% |
| Q1 2017 | 2017-04-02 | $12.78B | −$226.0M | −1.74% |
| Q4 2016 | 2016-12-31 | $13.63B | −$420.0M | −2.99% |
| Q3 2016 | 2016-10-02 | $13.04B | $958.0M | +7.93% |
| Q2 2016 | 2016-07-03 | $13.15B | $1.29B | +10.92% |
| Q1 2016 | 2016-04-03 | $13.01B | $2.14B | +19.71% |
| Q4 2015 | 2015-12-31 | $14.05B | $929.0M | +7.08% |
| Q3 2015 | 2015-09-27 | $12.09B | −$274.0M | −2.22% |
| Q2 2015 | 2015-06-28 | $11.85B | −$920.0M | −7.20% |
| Q1 2015 | 2015-03-29 | $10.86B | −$489.0M | −4.31% |
| Q4 2014 | 2014-12-31 | $13.12B | −$440.0M | −3.25% |
| Q3 2014 | 2014-09-28 | $12.36B | −$282.0M | −2.23% |
| Q2 2014 | 2014-06-29 | $12.77B | −$200.0M | −1.54% |
| Q1 2014 | 2014-03-30 | $11.35B | −$1.06B | −8.52% |
| Q4 2013 | 2013-12-31 | $13.56B | $707.0M | +5.50% |
| Q3 2013 | 2013-09-29 | $12.64B | −$310.0M | −2.39% |
| Q2 2013 | 2013-06-30 | $12.97B | −$995.0M | −7.12% |
| Q1 2013 | 2013-03-31 | $12.41B | −$2.48B | −16.63% |
| Q4 2012 | 2012-12-31 | $12.85B | $1.91B | +17.47% |
| Q3 2012 | 2012-09-30 | $12.95B | −$3.66B | −22.01% |
| Q2 2012 | 2012-07-01 | $13.97B | −$3.02B | −17.76% |
| Q1 2012 | 2012-04-01 | $14.88B | −$1.62B | −9.80% |
| Q4 2011 | 2011-12-31 | $10.94B | −$4.52B | −29.25% |
| Q3 2011 | 2011-10-02 | $16.61B | $614.0M | +3.84% |
| Q2 2011 | 2011-07-03 | $16.98B | −$148.0M | −0.86% |
| Q1 2011 | 2011-04-03 | $16.50B | −$74.0M | −0.45% |
| Q4 2010 | 2010-12-31 | $15.46B | −$335.0M | −2.12% |
| Q3 2010 | 2010-10-03 | $15.99B | $4.37B | +37.64% |
| Q2 2010 | 2010-07-04 | $17.13B | $6.15B | +55.97% |
| Q1 2010 | 2010-04-04 | $16.58B | $5.71B | +52.54% |
| Q4 2009 | 2009-12-31 | $15.80B | — | — |
| Q3 2009 | 2009-09-27 | $11.62B | −$352.0M | −2.94% |
| Q2 2009 | 2009-06-28 | $10.98B | −$1.15B | −9.44% |
| Q1 2009 | 2009-03-29 | $10.87B | — | — |
| Q3 2008 | 2008-09-28 | $11.97B | — | — |
| Q2 2008 | 2008-06-29 | $12.13B | — | — |
Pfizer revenue growth trends
Over the last five reported fiscal years, revenue grew from $41.65B to $62.58B, a compound annual growth rate of 8.48%. Pfizer's latest reported quarter, Q2 2026, generated $15.03B in revenue, an increase of 2.60% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Pfizer source filings ↗